"I'm particularly excited about this agent because it's a novel mechanism in antiviral action," said Frederick Hayden, a professor of medicine and pathology at the UVA School of Medicine who was among a group of researchers studying Xofluza in the U.S. and Japan. "We haven't had any new influenza drugs in term of how they work in inhibiting the virus in about 20 years."